Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725366 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4376268 | 0.97 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5969961 | 0.97 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4376272 | 0.97 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL13863051 | 0.96 | ADORA2A (0.95) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723460 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723466 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723596 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723603 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723528 | 0.95 | ADORA2A (0.91) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | PFIZER INC. | 2004-09-02 | — | — | US | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| US-8883500-B2 | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy | NORTHEASTERN UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | PFIZER INC. | 2004-09-02 | — | — | US | disclosed |
| US-6525032-B2 | Agonists of human adenosine receptors useful as anti-inflammatory agents in treatment of diseases of respiratory tract; chemical intermediates | PFIZER INC | 2003-02-25 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| US-20010020089-A1 | Purine derivatives | PFIZER INC. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020089-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA2B 4/4885 |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.